+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cholera Vaccine Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

  • ID: 4828905
  • Report
  • February 2019
  • Region: Global
  • 149 pages
  • Allied Analytics LLP
1 of 4
Cholera Vaccine Market Overview:

The global cholera vaccine market generated $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025.

Cholera is an acute intestinal infection that causes rapidly dehydrating diarrheal disease, which is caused by toxigenic serogroups of the bacterium Vibrio cholera. The disease is closely associated with poverty, poor sanitation, and lack of clean drinking water. Historically, devastating outbreaks of cholera resulted in millions of cases and hundreds of thousands of deaths. Currently, cholera remains an important public health problem in many countries, occurring as an endemic disease in some regions and causing major epidemics in some low- and middle-income countries (LMICs). The vaccine is used to control cholera and is mainly recommended for travelers and the people living in cholera-affected region.

There is an increase in the demand for cholera vaccine due to lack of proper sanitation & consumption of contaminated food and growth in the awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players.

The global cholera vaccine market is segmented based on product, end user, and region. Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. Depending on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits For Cholera Vaccine Market:

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global cholera vaccine market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

Cholera Vaccine Key Market Segments:

By Product

Dukoral
Shanchol
Vaxchora
Euvichol & Euvichol-Plus
Others

By End User

Hospitals & Clinics
Research & Academic Laboratories
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Sweden
Rest of Europe
Asia-Pacific
Australia
Japan
India
Vietnam
Rest of Asia-Pacific
LAMEA
Nigeria
Malawi
Zambia
Rest of LAMEA

Key Market Players

Valneva SE
Emergent BioSolutions, Inc. (PaxVax, Inc.)
Astellas Pharma, Inc.
Sanofi (Shantha Biotechnics Private Limited)
Eubiologics Co., Ltd.
Johnson & Johnson (Crucell)
Celldex Therapeutics, Inc.

The other players in the value chain include (profiles not included in the report):
Merck & Co., Inc.
GlaxoSmithKline plc.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top Player Positioning, 2017
3.4. Porters five forces analysis
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Lack of proper sanitation and consumption of contaminated food
3.5.1.2. Rise in awareness about cholera preventive care
3.5.1.3. Development of novel approaches for new cholera vaccine
3.5.2. Restraints
3.5.2.1. Risk of adverse effects
3.5.2.2. The time taken for the regulatory approval
3.5.3. Opportunities
3.5.3.1. High growth opportunities in untapped markets

CHAPTER 4: CHOLERA VACCINE MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Dukoral
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Shanchol
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Vaxchora
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Euvichol & Euvichol-Plus
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Others
4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: CHOLERA VACCINE MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals & Clinics
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Research & Academic Laboratories
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: CHOLERA VACCINE MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America cholera vaccine market, by country
6.2.2.1. U.S. cholera vaccine market by product
6.2.2.2. U.S. cholera vaccine market by end user
6.2.2.3. Canada cholera vaccine market by product
6.2.2.4. Canada cholera vaccine market by end user
6.2.2.5. Mexico cholera vaccine market by product
6.2.2.6. Mexico cholera vaccine market by end user
6.2.3. North America cholera vaccine market, by product
6.2.4. North America cholera vaccine market, by end user
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe cholera vaccine market, by country
6.3.2.1. Germany cholera vaccine market by product
6.3.2.2. Germany cholera vaccine market by end user
6.3.2.3. France cholera vaccine market by product
6.3.2.4. France cholera vaccine market by end user
6.3.2.5. UK cholera vaccine market by product
6.3.2.6. UK cholera vaccine market by end user
6.3.2.7. Italy cholera vaccine market by product
6.3.2.8. Italy cholera vaccine market by end user
6.3.2.9. Sweden cholera vaccine market by product
6.3.2.10. Sweden cholera vaccine market by end user
6.3.2.11. Rest of Europe cholera vaccine market by product
6.3.2.12. Rest of Europe cholera vaccine market by end user
6.3.3. Europe cholera vaccine market, by product
6.3.4. Europe cholera vaccine market, by end user
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific cholera vaccine market, by country
6.4.2.1. Australia cholera vaccine market by product
6.4.2.2. Australia cholera vaccine market by end user
6.4.2.3. Japan cholera vaccine market by product
6.4.2.4. Japan cholera vaccine market by end user
6.4.2.5. India cholera vaccine market by product
6.4.2.6. India cholera vaccine market by end user
6.4.2.7. Vietnam cholera vaccine market by product
6.4.2.8. Vietnam cholera vaccine market by end user
6.4.2.9. Rest of Asia-Pacific cholera vaccine market by product
6.4.2.10. Rest of Asia-Pacific cholera vaccine market by end user
6.4.3. Asia-Pacific cholera vaccine market, by product
6.4.4. Asia-Pacific cholera vaccine market, by end user
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA cholera vaccine market, by country
6.5.2.1. Nigeria cholera vaccine market by product
6.5.2.2. Nigeria cholera vaccine market by end user
6.5.2.3. Malawi cholera vaccine market by product
6.5.2.4. Malawi cholera vaccine market by end user
6.5.2.5. Zambia cholera vaccine market by product
6.5.2.6. Zambia cholera vaccine market by end user
6.5.2.7. Rest of LAMEA cholera vaccine market by product
6.5.2.8. Rest of LAMEA cholera vaccine market by end user
6.5.3. LAMEA cholera vaccine market, by product
6.5.4. LAMEA cholera vaccine market, by end user

CHAPTER 7: COMPANY PROFILES
7.1. Astellas Pharma, Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Business performance
7.2. Celldex Therapeutics, Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Business performance
7.2.4. Key strategic moves and developments
7.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.4. Eubiologics Co., Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.5. Johnson & Johnson (Crucell)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.6. Sanofi (Shantha Biotechnics Private Limited)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to this report titled 'Cholera Vaccine Market by Product and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,' the global cholera vaccine market generated $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025. The Dukoral segment accounted around half of the total market share in 2017.

Cholera is an acute, profusely watery diarrhea caused by Vibrio cholera and spreads through contamination of water and food. In addition, it is closely associated with poor sanitation and lack of clean drinking water. The number of global cholera disease cases accounts for around 35 million every year. Currently, the frequency of cholera epidemics has increased mainly in low- and middle-income countries. Cholera control is the main priority in cholera-endemic areas, which in turn increase the demand for the cholera vaccines.

The cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and growth in awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players in the near future.

Based on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. The hospitals & clinics segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that hospitals and clinics are authorized to organize campaigns for cholera vaccination, as the number of cases for cholera diseases is rapidly growing in LMICs.

Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the number of travelers to the cholera-affected countries is increasing, which in turn increases the demand for immunization.

The report provides a comprehensive analysis of the key players operating in the global cholera vaccine market industry, namely Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and Johnson & Johnson (Crucell), Celldex Therapeutics, Inc. The other players in the in the cholera vaccine market industry include Merck & Co., Inc., GlaxoSmithKline plc., and others.

Key Findings Of The Study

Based on product, the Vaxchora segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to 2025.
Depending on end user, the pharmaceutical & biotechnology companies segment is expected to exhibit the highest CAGR during the forecast period.
U.S. generated the highest revenue in the global cholera vaccine market industry in 2017, accounting less than one-tenth of the global market in 2017.

North America is estimated to grow at a CAGR of 17.1% during the forecast period.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll